Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1998 1
2003 2
2006 1
2008 1
2014 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
Miehlke S, Madisch A, Kupcinskas L, Petrauskas D, Böhm G, Marks HJ, Neumeyer M, Nathan T, Fernández-Bañares F, Greinwald R, Mohrbacher R, Vieth M, Bonderup OK; BUC-60/COC Study Group. Miehlke S, et al. Gastroenterology. 2014 May;146(5):1222-30.e1-2. doi: 10.1053/j.gastro.2014.01.019. Epub 2014 Jan 15. Gastroenterology. 2014. PMID: 24440672 Free article. Clinical Trial.
One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.
Miehlke S, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Haferland C, Bästlein E, Jebens C, Zekorn C, Knoth H, Stolte M, Lehn N. Miehlke S, et al. Among authors: haferland c. Helicobacter. 2008 Feb;13(1):69-74. doi: 10.1111/j.1523-5378.2007.00588.x. Helicobacter. 2008. PMID: 18205669 Clinical Trial.
A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Miehlke S, Kirsch C, Schneider-Brachert W, Haferland C, Neumeyer M, Bästlein E, Papke J, Jacobs E, Vieth M, Stolte M, Lehn N, Bayerdörffer E. Miehlke S, et al. Among authors: haferland c. Helicobacter. 2003 Aug;8(4):310-9. doi: 10.1046/j.1523-5378.2003.00158.x. Helicobacter. 2003. PMID: 12950604 Clinical Trial.
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance.
Miehlke S, Schneider-Brachert W, Bästlein E, Ebert S, Kirsch C, Haferland C, Buchner M, Neumeyer M, Vieth M, Stolte M, Lehn N, Bayerdörffer E. Miehlke S, et al. Among authors: haferland c. Aliment Pharmacol Ther. 2003 Oct 15;18(8):799-804. doi: 10.1046/j.1365-2036.2003.01764.x. Aliment Pharmacol Ther. 2003. PMID: 14535873 Free article. Clinical Trial.
7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
Antos D, Schneider-Brachert W, Bästlein E, Hänel C, Haferland C, Buchner M, Meier E, Trump F, Stolte M, Lehn N, Bayerdörffer E. Antos D, et al. Among authors: haferland c. Helicobacter. 2006 Feb;11(1):39-45. doi: 10.1111/j.0083-8703.2006.00375.x. Helicobacter. 2006. PMID: 16423088 Clinical Trial.
[Genetically based disorders of the inner ear].
Kessler L, Haferland C. Kessler L, et al. Among authors: haferland c. Cesk Otolaryngol. 1980 Jan;29(1):21-4. Cesk Otolaryngol. 1980. PMID: 7371085 Czech. No abstract available.